Satavaptan treatment for ascites in patients with cirrhosis: A meta-analysis of effect on hepatic encephalopathy development

Metabolic Brain Disease

Volumn 28, Issue 2, 2013, Pages 301-305

  Watson, Hugh ^a   Jepsen, Peter ^b   Wong, Florence ^c   Ginès, Pere ^d   Córdoba, Juan ^e   Vilstrup, Hendrik ^b  

^a SANOFI   (France)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Hepatic encephalopathy; Hyponatraemia; Satavaptan; Vasopressin

Indexed keywords

SATAVAPTAN; SODIUM; MORPHOLINE DERIVATIVE; SPIRO COMPOUND; VASOPRESSIN RECEPTOR ANTAGONIST;

ASCITES; CONFERENCE PAPER; DRUG EFFICACY; HEPATIC ENCEPHALOPATHY; HUMAN; HYPONATREMIA; LIVER CIRRHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SODIUM BLOOD LEVEL; COMPLICATION; KAPLAN MEIER METHOD; META ANALYSIS; METHODOLOGY; MULTICENTER STUDY (TOPIC); SURVIVAL;

ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; ASCITES; HEPATIC ENCEPHALOPATHY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; MORPHOLINES; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SPIRO COMPOUNDS; SURVIVAL ANALYSIS;

EID: 84878020534     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-013-9384-4     Document Type: Conference Paper

References (15)

1. Angeli P, Wong F, Watson H, Ginès P, CAPPS investigators (2006) Hyponatraemia in cirrhosis: results of a patient population survey. Hepatology 44:1535-1542
2. Cardenas A, Ginès P, Marotta P, Czerwiec F, Oyuang J, Guevara M, Afdhal NH (2012) Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol 56:571-578
3. Cordoba J, Guevara M, Watson HR, Le Guennec S, Ginès P (2009) Improvement of hyponatremia in cirrhosis increases speed of complex information processing. Hepatology 50(4) (suppl):451A
4. Decaux G, Soupart A, Vassart G (2008) Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371:1624-1632
5. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei A (2002) Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35:716-721
6. Gerbes AL, Gülberg VA, Ginès P, Decaux G, Gross P, Gandjini H, Djian J, VPA study group (2003) Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized, double-blind multicenter trial. Gastroenterology 124:933-939
7. Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D, HypoCAT Study Investigators (2008) Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 48:204-213
8. 2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatremia - a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 31:834-845
9. Guevara M, Baccaro ME, Torre A, Gómez-Ansón B, Ríos J, Torres F, Rami L, Monté-Rubio GC, Martín-Llahí M, Arroyo V, Ginès P (2009) Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol 104:1382-1389
10. Guevara M, Baccaro ME, Rios J, Martín-Llahí M, Uriz J, Ruiz del Arbol L, Planas R, Monescillo A, Guarner C, Crespo J, Bañares R, Arroyo V, Ginès P (2010) Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int. doi: 10.1111/j.1478-3231.2010.02293.x
11. Restuccia T, Gómez-Ansón B, Guevara M, Alessandria C, Torre A, Alayrach ME, Terra C, Martín M, Castellví M, Rami L, Sainz A, Ginès P, Arroyo V (2004) Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. Hepatology 39:1613-1622
12. Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A, Attili AF, Merli M (2008) Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol 103:2738-2746
13. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C, SALT Investigators (2006) Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. New Engl J Med 355:2099-2112
14. Wong F, Ginès P, Watson H, Horsmans Y, Angeli P, Gow P, Minini P, Bernardi M (2010) Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol 53:283-290
15. Wong F, Watson H, Gerbes A, Vilstrup H, Badalamenti S, Bernardi M, Ginès P (2012) Satavaptan for the management of ascites in cirrhosis; efficacy and safety across the spectrum of ascites severity. Gut 61:108-116